JM-4

N/A

Report date: 2025/01/26 18:06:11

Base Information

Drug NameJM-4
Drug Alias Nameerythropoietin peptide fragment (VA New Jersey Health Care System/Rutgers)JM-4
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsBrain Injuries, TraumaticBrain DiseasesGuillain-Barre Syndrome +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVA New Jersey Health Care System
China Registration ClassN/A

Develop Information

Active CompaniesVA New Jersey Health Care SystemRutgers University
Inactive CompaniesN/A
Active IndicationsBrain Injuries, TraumaticBrain DiseasesGuillain-Barre Syndrome +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A